Portfolio articles – Sound Bioventures

All Events Fund articles Fund PR Portfolio articles Portfolio PR

Navigating the journey of orphan drug development

2024.06.282024.06.28 / A new drug rarely takes a direct path from idea to patient, especially a first-in-class therapy. For NephroDI Therapeutics, developing a novel approach addressing the critical unmet medical need of a ...

Johan Kördel Ph.D., Managing Partner - Sound Bioventures

Sound Bioventures: Putting Scandinavian Biotechs on the Global Stage

2024.06.042024.09.09 / In this keynote presentation from the BioStock Global Forum, Sound Bioventures' Managing Partner Johan Kordel discusses the importance of Scandinavian biotch companies taking a strong international p ...

Evolving to the next phase of viral therapy development

2024.05.012024.05.13 / UK-based Theolytics is about to begin the first clinical trials for one of its cancer-fighting viruses. It’s a major step for any biotech company, often reached only after years of adjusting and read ...

Sound Bioventures joins £19M ($24.5M) financing in UK oncolytic virus company Theolytics

2024.04.172024.05.13 / Sound Bioventures joins strong international syndicate comprising M Ventures, Taiho Ventures, Epidarex Capital, Oxford Science Enterprises and the University of Oxford New funding enables Theolyt ...

VC Investing in Clinical Stage Biotherapeutics Companies in Europe and the U.S.

2024.02.022024.02.02 / In this episode of Engaging Alternatives Spotlight, Elana Margulies-Snyderman, Director, Publications, EisnerAmper, speaks with Bibhash Mukhopadhyay, Managing Partner, Sound Bioventures, a ventur ...

Sound Bioventures 2023 year in review

2024.01.302024.01.31 / A busy year with the final close of Sound Bioventures Fund I 2023 was a busy year for Sound Bioventures with the final close of Sound Bioventures Fund I taking the final total capital commitments ...

The oral therapeutic that could change our approach to retinal disease. An inflammation-based view of both ophthalmic and neurologic health

2023.11.032024.05.13 / Dr Burian said oral therapies can also function in conjunction with therapies currently on the market. In late July, biotech incubator Golgi Neurosciences S.r.l. and biopharmaceutical company Bre ...

Bringing everything together for an autoimmunity game changer

2023.09.202024.05.13 / At AbolerIS Pharma, it's all about creating balance. The Belgian/French biotech company is gearing up for clinical trials of a novel therapy for stabilizing chaotic immune systems. As CEO Ann Meulema ...

Reaching the next level of creating novel therapies for genetic diseases

2023.05.312024.05.13 / ARTHEx Biotech is entering a new phase in its development of breakthrough treatments for genetically-driven disorders. It’s set to begin the first clinical trials for one of its microRNA modulators a ...

The drive to adapt a lab discovery into treatment of neurodegeneration

2023.03.292024.05.13 / Teitur Trophics is breaking new ground when it comes to neurodegenerative diseases. After identifying a previously unknown means of preserving functioning brain cells, the biotech company’s founders ...

From toxin to remedy, and operating room to the boardroom

2023.03.212024.09.11 / Even though it’s based on venom from one of the deadliest snakes in the world, the lead product of biotech startup VarmX can be life-saving for patients on blood thinners. It's an unexpected turn, bu ...

Read about Artax Biopharma and their journey developing a revolutionary therapy for autoimmune diseases that makes a meaningful difference in patients lives.

A patient-centric mission for life-changing autoimmune treatments

2023.02.232024.05.13 / Artax Biopharma is committed to radical innovation. But for the US-based biotech company and CEO Joseph Lobacki, the only innovations that truly matter are the ones that make a meaningful differe ...